ICD-10-CM 2027 diagnosis code
T80.82XAComplication of immune effector cellular therapy, initial encounter
T80.82XA is a valid, billable ICD-10-CM code for complication of immune effector cellular therapy, initial encounter. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Complication of immune effector cellular therapy, init
Code last changed in FY2022 (effective October 1, 2021). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About T80.82XA
T80.82XA is the ICD-10-CM diagnosis code for complication of immune effector cellular therapy, initial encounter. It belongs to category T80 (complications following infusion, transfusion and therapeutic injection), block T80-T88 (complications of surgical and medical care, not elsewhere classified) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
The 7th character "A" means initial encounter: use it while the patient is receiving active treatment for the condition.
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 791 (Prematurity with Major Problems, relative weight 4.1075), DRG 793 (Full Term Neonate with Major Problems, relative weight 4.2195), DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 15 (Newborns and Other Neonates with Conditions Originating in the Perinatal Period) and MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It was added in FY2022, effective October 1, 2021.
7th character
Ainitial encounter
Other encounter types for T80.82:
Notes that apply from higher levels
Instructions written at a parent level also apply to T80.82XA.
› From T80.82 Complication of immune effector cellular therapy
› From T80 Complications following infusion, transfusion and therapeutic injection
- complications following perfusion
- bone marrow transplant rejection (T86.01)
- febrile nonhemolytic transfusion reaction (R50.84)
- fluid overload due to transfusion (E87.71)
- posttransfusion purpura (D69.51)
- transfusion associated circulatory overload (TACO) (E87.71)
- transfusion (red blood cell) associated hemochromatosis (E83.111)
- transfusion related acute lung injury (TRALI) (J95.84)
Broader instructions also apply from T80-T88 Complications of surgical and medical care, not elsewhere classified and Chapter 19: Injury, poisoning and certain other consequences of external causes.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 15 · Newborns and Other Neonates with Conditions Originating in the Perinatal Period
MDC 15 · Newborns and Other Neonates with Conditions Originating in the Perinatal Period
MDC 16 · Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2022 (effective 10/1/2021): Added
- No changes since FY2022.
Common questions about T80.82XA
Is T80.82XA billable?
- Yes. T80.82XA is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
What does the "A" at the end of T80.82XA mean?
- It is the 7th character for initial encounter. Per the official guidelines, use it while the patient is receiving active treatment for the condition.
Can T80.82XA be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict T80.82XA as a principal diagnosis.
Is T80.82XA a CC or MCC?
- No. T80.82XA is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does T80.82XA group to?
- T80.82XA is used in the MS-DRG v44.0 logic for MS-DRG 791 (Prematurity with Major Problems), MS-DRG 793 (Full Term Neonate with Major Problems), MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.